Selecta Biosciences PE Ratio 2015-2021 | SELB

Current and historical p/e ratio for Selecta Biosciences (SELB) from 2015 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Selecta Biosciences PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Selecta Biosciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 4.27 0.00
2021-06-30 4.18 $-0.45 0.00
2021-03-31 4.53 $-0.70 0.00
2020-12-31 3.03 $-0.69 0.00
2020-09-30 2.48 $-0.83 0.00
2020-06-30 2.84 $-1.00 0.00
2020-03-31 2.41 $-1.12 0.00
2019-12-31 2.38 $-1.22 0.00
2019-09-30 1.75 $-1.59 0.00
2019-06-30 1.79 $-2.04 0.00
2019-03-31 2.37 $-2.51 0.00
2018-12-31 2.66 $-2.91 0.00
2018-09-30 15.55 $-3.14 0.00
2018-06-30 13.25 $-3.09 0.00
2018-03-31 10.19 $-3.10 0.00
2017-12-31 9.81 $-3.21 0.00
2017-09-30 18.25 $-3.10 0.00
2017-06-30 19.86 $-2.87 0.00
2017-03-31 14.32 $-4.77 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.491B $0.017B
Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00